WR Wealth Planners LLC Buys 411 Shares of Pfizer Inc. (NYSE:PFE)

WR Wealth Planners LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 7.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,133 shares of the biopharmaceutical company’s stock after buying an additional 411 shares during the quarter. WR Wealth Planners LLC’s holdings in Pfizer were worth $172,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Nilsine Partners LLC lifted its holdings in Pfizer by 31.8% during the second quarter. Nilsine Partners LLC now owns 17,381 shares of the biopharmaceutical company’s stock valued at $486,000 after purchasing an additional 4,197 shares in the last quarter. International Private Wealth Advisors LLC purchased a new position in shares of Pfizer during the 2nd quarter valued at $428,000. CWS Financial Advisors LLC boosted its holdings in Pfizer by 14.7% in the 2nd quarter. CWS Financial Advisors LLC now owns 27,158 shares of the biopharmaceutical company’s stock worth $760,000 after buying an additional 3,490 shares during the period. nVerses Capital LLC increased its stake in Pfizer by 662.5% in the 2nd quarter. nVerses Capital LLC now owns 6,100 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 5,300 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in Pfizer by 28.4% during the second quarter. Farther Finance Advisors LLC now owns 54,843 shares of the biopharmaceutical company’s stock valued at $1,548,000 after acquiring an additional 12,131 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. UBS Group increased their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Barclays raised their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Wells Fargo & Company boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Trading Up 1.0 %

NYSE PFE traded up $0.29 during trading hours on Friday, hitting $29.01. 37,137,599 shares of the company were exchanged, compared to its average volume of 26,838,326. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $36.29. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The stock has a 50-day moving average price of $28.99 and a 200 day moving average price of $28.01. The stock has a market cap of $164.39 billion, a PE ratio of -483.42, a price-to-earnings-growth ratio of 1.02 and a beta of 0.69.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.67 EPS. Analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.79%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.